Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug intented for treatment of chronic atopic dermatitis
Subscribe to our email newsletter
Welichem Biotech has announced the filing with Health Canada of a clinical trial application for its lead, anti-inflammatory drug WBI-1001. The application is for a 3-month, double blinded clinical trial in patients with chronic atopic dermatitis at three trial centres.
The filing is a direct result of the successful completion of the long-term, IND-enabling toxicology studies announced April, 2009. Results of the long-term toxicology studies support additional, longer term clinical trials of WBI-1001.
The company said that Welichem’s plans for the international phase II/III clinical program as it builds on the successfully completed clinical trials and safety studies of WBI-1001.
WBI-1001 is a non-steroidal, anti-inflammatory drug candidate that has been shown in prior clinical trials to be effective and to have good safety profile. WBI-1001 is a novel, patented drug candidate that is being developed by Welichem as a new treatment for AD, psoriasis and related diseases.
Genhui Chen, chief executive officer of Welichem Biotech, said: “We are very encouraged by the data on this non-steroidal, anti-inflammatory drug candidate. This application is a significant step forward in our drug development program.”